Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0LNYUS
ADC Name	WO2022057651A1 ADC-21
Synonyms	WO2022057651A1 ADC 21 Click to Show/Hide
Organization	Sichuan Kelun Pharmaceutical Co., Ltd.
Drug Status	Investigative
Indication	In total 4 Indication(s) Bladder cancer [ICD11:2C94] Investigative Breast cancer [ICD11:2C60-2C65] Investigative Lung cancer [ICD11:2C25] Investigative Non-small cell lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	7.98
Structure
	3D MOL	2D MOL
Antibody Name	74HZ		Antibody Info
Antigen Name	Nectin-4 (NECTIN4)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2022057651A1 ADC-21 linker

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Effective Concentration (EC50)	611.3	ng/mL	T-47D cells	Invasive breast carcinoma
Half Maximal Effective Concentration (EC50)	1.36	ug/mL	A-549 cells	Lung adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	611.30 ng/mL	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.36 ug/mL	High NECTIN4 expression (NECTIN4 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023

References

Ref 1	Anti-nectin-4 antibody, conjugate including same, and application thereof; 2022-03-24.